Dr Neal Shore

Go Back

Urologist

  • Carolina Urologic Research Center and GenesisCare
  • location United States

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Dr Neal Shore has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, Astellas, Amgen, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Lantheus, Lilly, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Photocure, Propella, PreView, Sanofi Genzyme, Sema4, Speciality Networks, Sesen Bio, Telix, Tempus, Tolmar and Urogen, Vaxiion.

Programmes developed by Dr Neal Shore

video Video

Episode

1

of 2

episode
Oncology 
Clinical implementation of testing and PARPi as monotherapy

Episode 1: Clinical implementation of testing and PARPi monotherapy

Experts
Dr Neal Shore
Endorsed by
ZERO NASPCC
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast

Episode

2

of 3

episode
Oncology 
PARP inhibitors alone or in combination with novel hormonal agents in prostate cancer

Episode 2: Clinical implementation of PARPi and NHA combination therapy for patients with mCRPC – a US and EU perspective

Experts
Dr Neal Shore, Dr Elena Castro
Endorsed by
ZERO
  • download Downloadable
    Resources
  • clock MIN
  • calendar Feb 2023

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast

Episode

1

of 3

episode
Oncology 
PARP inhibitors alone or in combination with novel hormonal agents in prostate cancer

Episode 1: Clinical implementation of PARPi monotherapy for prostate cancer patients – a US and EU perspective

Experts
Dr Neal Shore, Dr Elena Castro
Endorsed by
ZERO
  • download Downloadable
    Resources
  • clock MIN
  • calendar Feb 2023

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology 
Podcast: Timing of ARSI and taxanes for mCSPC

In this podcast Assoc. Prof. Tanya Dorff and Dr Neal Shore focus on patients with metastatic castration-sensitive prostate cancer (mCSPC) and discuss when to use androgen receptor signalling inhibitors (ARSI) and taxanes for these patients.

Experts
Assoc. Prof. Tanya Dorff, Dr Neal Shore
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2022

Educational programme supported by an Independent Educational Grant from Bayer